ImageneBio, Inc. SEC filings IMA
ImageneBio, Inc. has 336 filings in SEC EDGAR's recent list, going back to Jan 8, 2021. Its latest annual report, Form ARS, was filed on Apr 30, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 5, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Aug 5, 2026 (results of operations). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| EFFECT | Filing | Aug 11, 2026 | — |
| EFFECT | Filing | Aug 11, 2026 | — |
| EFFECT | Filing | Aug 6, 2026 | — |
| EFFECT | Filing | Apr 3, 2026 | — |
| EFFECT | Filing | Sep 15, 2025 | — |
| CORRESP | Letter to the SEC | Sep 11, 2025 | — |
| UPLOAD | Letter from the SEC | Sep 11, 2025 | — |
| D | Filing | Jul 18, 2025 | — |
| 425 | Filing | Jul 11, 2025 | — |
| 425 | Filing | Jul 1, 2025 | — |
| EFFECT | Filing | Jun 11, 2025 | — |
| CORRESP | Letter to the SEC | Jun 10, 2025 | — |
| CORRESP | Letter to the SEC | Jun 9, 2025 | — |
| UPLOAD | Letter from the SEC | Jun 3, 2025 | — |
| CORRESP | Letter to the SEC | May 7, 2025 | — |
| UPLOAD | Letter from the SEC | May 2, 2025 | — |
| CORRESP | Letter to the SEC | Apr 21, 2025 | — |
| UPLOAD | Letter from the SEC | Apr 14, 2025 | — |
| 425 | Filing | Jan 10, 2025 | — |
| 425 | Filing | Dec 23, 2024 | — |
| EFFECT | Filing | Sep 8, 2023 | — |
| CORRESP | Letter to the SEC | Sep 6, 2023 | — |
| D | Filing | Aug 18, 2023 | — |
| EFFECT | Filing | May 5, 2022 | — |
| CORRESP | Letter to the SEC | May 3, 2022 | — |
| UPLOAD | Letter from the SEC | May 2, 2022 | — |
| EFFECT | Filing | Mar 25, 2021 | — |
| SEC STAFF LETTER | Filing | Mar 25, 2021 | — |
| CERT | Filing | Mar 25, 2021 | — |
| 8-A12B | Filing | Mar 23, 2021 | — |
| CORRESP | Letter to the SEC | Mar 23, 2021 | — |
| CORRESP | Letter to the SEC | Mar 23, 2021 | — |
| CORRESP | Letter to the SEC | Mar 12, 2021 | — |
| CORRESP | Letter to the SEC | Mar 5, 2021 | — |
| SEC STAFF LETTER | Filing | Mar 1, 2021 | — |
| UPLOAD | Letter from the SEC | Feb 25, 2021 | — |
| DRSLTR | Filing | Feb 11, 2021 | — |
| DRS/A | Filing | Feb 11, 2021 | — |
| UPLOAD | Letter from the SEC | Feb 8, 2021 | — |
| DRS | Filing | Jan 8, 2021 | — |
Showing 40 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Biological Products, (No Diagnostic Substances) (SIC 2836)
- Listed as
- IMA (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- San Diego, CA
- SEC filer status
- Non-accelerated filer, Smaller reporting company, Emerging growth company
- SEC CIK
- 1835579
- Former names
- Ikena Oncology, Inc. (until Jul 25, 2025)
Other Biological Products, (No Diagnostic Substances) companies
- Amgen Inc AMGN
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Argenx SE ARGX
- Revolution Medicines, Inc. RVMD
- Biogen Inc. BIIB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
All 182 Biological Products, (No Diagnostic Substances) companies
Source: SEC EDGAR filings. This is company-reported data, not investment advice.